Kelly Barta’s Story

Kelly Barta headshot

Kelly Barta
Coalition of Skin Diseases, President

After experiencing a prolonged and severe health crisis due to long-term use of topical steroids for eczema, Kelly became a passionate voice for those who were suffering. She was determined to bring change to the way eczema was understood and treated. Her advocacy efforts have led her to serve on several national dermatology nonprofits, bringing awareness to the great needs of this community and supporting those living with eczema and going through topical steroid withdrawal syndrome.

Kelly currently serves as President and CEO of the Coalition of Skin Diseases, an umbrella organization of more than 25 national skin-related patient groups, which exists to raise awareness of skin diseases and advocate for the 84+ million Americans living with skin conditions.

She has served as past president of the International Topical Steroid Awareness Network (ITSAN), and continues to support their mission as member of the Board of Directors. Additionally, Kelly sits on the Patient Advocacy Task Force of the American Academy of Dermatology and the Atopic Dermatitis Advisory Panel for Globalskin. She has presented on eczema and TSW to the FDA as well as before patient, academic and political audiences. Kelly is the recent author of her story, To Eczema With Love, https://toeczemawithlove.com/.

Kelly resides in Atlanta, Georgia with her two sons and enjoys taking in the great outdoors, whether it be the mountains, oceans, a walk in the woods or digging in her own garden.

The post Kelly Barta’s Story appeared first on Georgia Bio.

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS